Download Pipeline/Commercial Insight: Molecular Targeted Cancer

A Datamonitor report
Pipeline/Commercial Insight:
Molecular Targeted Cancer
Therapies – More Drugs on the
Market, More Targets in the
Pipeline
Providing you with:
Published: Sep-06
Product Code: DMHC2224
• Seven major pharmaceutical market sales
forecasts from 2005 to 2015 for approved
molecular targeted therapies and key
pipeline candidates
• Review of the current targeted therapies
market, including profiles, product-specific
assumptions and events over the forecasted
period
• Research and analysis of the targeted
therapies pipeline with in-depth clinical and
Use this report to...
Acquire a detailed appreciation and
impartial perspective of the targeted cancer
therapies market as a whole
commercial assessment of Phase III
candidates, plus expert opinion
• Examination of product pipeline by phase,
mode of action, indication, drug class and
developer, plus two commercial impact case
studies
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies – More Drugs on the Market, More Targets in the Pipeline
DMHC2224
Introduction
Cancer treatment continues to embrace the inclusion of molecular targeted
therapies (MTT) into standard treatment regimens. With an increasing number of
candidates gaining approval, and with a dynamic developmental pipeline, further
clinical, commercial and strategic challenges are continuing to emerge.
Since late 2005, four more MTTs have been launched. Both Nexavar (Bayer AG/Onyx) and
Sutent (Pfizer) have gained approval for kidney cancer with Sutent receiving approval in an
additional tumor type. Sprycel (Bristol-Myers Squibb), has been approved for Gleevec-resistant
CML patients and Amgen's fully-humanized monoclonal antibody, Vectibix has very recently
joined Erbitux and Avastin in the metastatic colorectal cancer market. These new agents are all
expected to perform well over the forecast period with an aggregate level of sales reaching
$2.77 billion in 2015.
Key findings and highlights
• In 2005, the MTT market was worth $7.5 billion and the forecast sales of already marketed
drugs in this class are expected to grow to $25.2 billion by 2015, at a CAGR of 12.9 per
cent. This growth will be driven mainly by Genentech/Roche's Rituxan, Herceptin and
Avastin as well as Novartis' Gleevec, all of which have already reached blockbuster status.
• 274 different pipeline MTTs have been identified. The introduction of current late-phase
candidates, including the pre-registered agents Tykerb (lapatinib; GlaxoSmithKline) and
Zolinza (vorinostat; Merck), will further increase the market's total value by $3.8 billion,
enabling the targeted therapies market to reach $29.1 billion in 2015.
• The rise in cost of cancer treatment is unsustainable with growing pharmacoeconomic
pressures challenging healthcare payers globally. To counter these hurdles, developers
must become more effective at communicating the value of their products. To this end, a
comprehensive understanding of the targeted therapies market and pipeline is critical.
Reasons to buy
• Acquire a detailed appreciation and impartial perspective of the targeted cancer therapies
market as a whole
• Consider and react to the specific events influencing the future potential of marketed and
pipeline targeted therapies
• Gain an insight into the emerging clinical, developmental and commercial challenges and
opportunities facing key developmental and marketed MTT drugs
Sample pages from the report
Pipeline Single-Target Signal
Transduction Inhibitors
Analysis & Forecasts
Not
Known
Not
Known
Temsirolimus
Zalutumumab
Wyeth
Research
Genmab
mTOR inhibitor
EGFR inhibitor
(hMAb)
Mantle cell
lymphoma and RCC
MM, melanoma,
glioma, NSCLC and
endometrial cancer
Head and neck
cancer
III
II
III
*Vectibix was approved by the FDA for relapsed/refractory metastatic colorectal cancer on September 27, 2006
See Abbreviations;
Source: R&D Focus, IMS Health, April 2006, Copyright ©, reprinted
with permission; IDdb3, July 2006, Copyright
Thomson Scientific; BioSpace; ClinicalTrials.gov
DATAMONITOR
Phase II pipeline single-target signal transduction
Pipelineinhibitors,
Angiogenesis
2006
Analysis & Forecasts
Table 42:
Brand
Drug
Company
Mode of action Indication
Certican
Omnitarg
Everolimus
Pertuzumab
Novartis AG
Genentech Inc
mTOR inhibitor Solid tumors
Her2 (ErbB2)
NSCLC, prostate, breast
inhibitor (hMAb) and ovarian cancers
Tracleer
Bosentan
Roche AG
Melanoma
Not
Known
AP-23573
ARIAD
Pharmaceuticals
Inc
Endothelin
ET-A receptor
inhibitor
mTOR inhibitor
Not
Known
Not
Known
CP-751871
Pfizer Inc
Various cancers
HKI-272
Wyeth Research
IGFR1 inhibitor
(hMAb)
Her2 (ErbB2)
TK inhibitor
Not
Known
Not
Known
Not
Known
Matuzumab
(EMD72000)
PEP-005
Merck KGaA
ZD-4054
AstraZeneca
Peplin Ltd
EGFR inhibitor
(hMAb)
PKC inhibitor
Endothelin ETA receptor
inhibitor
See Abbreviations
Source: R&D Focus, IMS Health, April 2006, Copyright ©,
reprinted with permission; IDdb3, July 2006,
Copyright Thomson Scientific; BioSpace;
ClinicalTrials.gov
Table 32:
© Datamonitor (Published 09/2006)
Phase II pipeline angiogenesis inhibitors, 2006
Glioma, sarcoma,
Brand leukemia,
Drug
endometrioid , lymphoma
and prostate
cancer Plitidepsin
Aplidin
Evizon
Squalamine
NSCLC and
breast cancer
Vitaxin, MEDI-522
Gastric, pancreatic,
Abegrin cervical
and ovarian cancers
Basal cell Not
carcinomaABT-510
Known
Prostate cancer
Not
Angiostatin
Known
Not
Axitinib
Known (AG-13736)
Not
CDP-791
Known
D A T A M OCilengitide
NITOR
Not
Known
Not
Known
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
Inhibitors
Combretastatin
CP-547632
Not
KnownDMHC2224
Not
Endostatin
Known Page 164
This report is a licensed product and is not to be photocopied
Not
Known
Not
Known
UK-356202
Not
Known
WX-UK1
Volociximab
Company
Mode of action
Indication
PharmaMar SA
VEGFR1 inhibitor
SCLC, AML, ALL, MM,
melanoma, NHL, prostate,
bladder and thyroid cancers
NSCLC, ovarian and prostate
cancers
CRC, Sarcoma, Melanoma,
prostate cancer
Genaera Corp
VEGF and Integrin
receptor inhibitor
Scripps Research Angiogenesis
Institute
inhibitor (Integrin
hMAb)
Abbott
Thrombospondin-1 NSCLC, RCC, sarcoma,
Laboratories
ligand, coagulation lymphoma
promoter and
angiogenesis
Pipeline Overview
inhibitor
EntreMed Inc
Angiogenesis
NSCLC
inhibitor
Pfizer Inc
VEGF, CSF-1, &
NSCLC, MDS, AML, RCC,
PDGF TK inhibitor melanoma and breast cancer
Celltech Group
VEGFR2 TK
NSCLC
plc
inhibitor
Merck KGaA
Integrin receptor TK NSCLC, Kaposi’s sarcoma,
inhibitor
CRC, glioma,
andmolecular targeted therapies by class of drug, 2006
Figure
2: melanoma
Pipeline
pancreatic and breast cancers
CRC, lung, prostate, thyroid,
OXiGENE
Cadherin-5
cervical, ovarian and
head &
antagonist and
Immunomodulatory
or
vascular damaging neck cancers
Immunoconjugated
Angiogenesis inhibitors
agent
therapeutics
44 (16%)
OSI
VEGF inhibitor
NSCLC and ovarian cancer
57 (21%)
Pharmaceuticals
Single-target signal
Children’s
Angiogenesis
Neuroendocrine tumors and
transduction inhibitors
Hospital of
inhibitor
melanoma
32 (12%)
Boston
Epigenetic modulators
Pfizer Inc
uPA inhibitor
Various cancers
16 (6%)
Eos
Biotechnology
Inc
Wilex
Angiogenesis
inhibitor (Integrin
MAb)
uPA inhibitor
See Abbreviations
Source: R&D Focus, IMS Health, April 2006, Copyright ©,
reprinted with permission; IDdb3, July 2006,
NSCLC, RCC, melanoma and
pancreatic cancer
Solid tumors
Cell cycle and
apoptosis targeted
agents
78 (28%)
Multi-targeted
inhibitors
47 (17%)
Copyright Thomson Scientific; BioSpace;
ClinicalTrials.gov
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
© Datamonitor (Published 09/2006)
This report is a licensed product and is not to be photocopied
DATAMONITOR
Source: Datamonitor
DATAMONITOR
The cell cycle and apoptosis targeted agents make up the largest number of
molecular targeted therapies (MTTs) in the developmental pipeline with 78
candidates inDMHC2224
all. This is largely due to the number of products from this class in
Phase I and Phase
II. While Millennium Pharmaceuticals’ Velcade is an apoptosis
Page 134
stimulator that has reached the market and achieved success in the treatment of
multiple myeloma, another product in this class, Genta’s Genasense, has suffered
significant setbacks in its commercialization. As evidenced here, although Genasense
has been at an advanced stage of development for several years, its numerous
setbacks have not deterred other developers from pursuing a similar anticancer drug
development strategy.
It is also important to note that while, for the purposes of this report, multi-targeted
agents have been classified as a separate subclass of MTTs, their mode of action is
largely through inhibition of signal transduction or angiogenesis drivers. In light of this,
the number of MTTs in development that are classified as single-target signal
transduction inhibitors (32, 12%), angiogenesis inhibitors (44, 16%) and multitargeted inhibitors (47, 17%) must be appreciated in context.
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
© Datamonitor (Published 09/2006)
DMHC2224
Page 27
This report is a licensed product and is not to be photocopied
“...We've got to figure out a way to know if we've actually hit the target. There's got to
be some blood tests that you can push and say OK, we've maximally inhibited VEGF
and then assume that's going to be the most efficacious dose and move forward...”
US opinion leader,
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies – More Drugs on the Market, More Targets in the Pipeline
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies – More Drugs on the Market, More Targets in the Pipeline
DMHC2224
Table of contents
ABOUT DATAMONITOR HEALTHCARE
• About the Oncology pharmaceutical analysis team
EXECUTIVE SUMMARY
• Scope of analysis
• Datamonitor insight into the targeted therapies
market
PIPELINE OVERVIEW
• Pipeline overview
• Pipeline by developmental phase and class of drug
- The cell cycle and apoptosis targeted agents make
up the largest number of MTTs in the pipeline
- Segmentation of drugs by developmental phase
reflects attrition rate of drug development in the
oncology market
• Pipeline by indication
- MTTs are being investigated in 29 different
cancers
• Pipeline by mode of action
- Pipeline MTTs are being directed against a huge
variety and combination of molecular targets
- The VEGF/VEGFR family remains the focus of
development for MTTs
• Pipeline by company
- There are over 150 different companies
developing targeted therapies
- Top three companies in terms of number of
pipeline MTT products are Pfizer, Novartis and
GlaxoSmithKline
• Key metrics
• Datamonitor pipeline assessment summary
PIPELINE DYNAMICS
• A diverse range of disease subtypes
• Genetic basis of cancer evolution
- Tumorigenesis is the result of co-operative
accumulated mutations
• Existing pharmacotherapy approaches provide
limited treatment benefit
- Cytotoxic drugs lack specificity
- Hormonal or endocrine therapy provides
incremental benefit in selected tumors
- Optimizing current treatment strategies is
paramount
• The emergence of targeted treatment heralds a
revolution in cancer pharmacotherapy
• Dynamic cancer market offers significant
commercial opportunity
- Ongoing sales growth drives the market
- Intensive R&D produces a rich developmental
pipeline
- Growing patient population and significant unmet
needs propel innovation in the cancer market
• Clinical and strategic threats to the
commercialization of cancer drugs
- Progressively rising R&D costs threaten industry
productivity
- Pharmacoeconomic pressures drive payers to
implement restrictive pricing and reimbursement
policies
- Therapeutic and generic competition reduces
periods of market exclusivity
- Segmentation of market will require changes in
clinical trial methodology
MARKET DEFINITION & PIPELINE CLASSIFICATION
• Targeted therapies overview
- The development of molecular targeted therapies
• Market definition
- L1X3 - Antineoplastic monoclonal antibodies
- L1X9 - All other antineoplastics
• Classification of pipeline products
- Angiogenesis inhibitors
- Single-target signal transduction inhibitors
- Multi-targeted inhibitors
- Cell cycle and apoptosis targeted inhibitors
- Epigenetic modulators
- Immunomodulatory and immunoconjugated
therapeutics
• Pipeline comparator
• Current market situation
MARKETED PRODUCTS FORECAST ANALYSIS
• Country-specific assumptions and effects
- Effect of Medicare Modernization Act in the US
- Biennial price cuts in Japan
- National Institute of Clinical Excellence in the UK
- Generic erosion assumptions
• Product assumptions and effects
- Angiogenesis inhibitors
- Single-target signal transduction inhibitors
- Multi-targeted inhibitors
- Cell cycle and apoptosis targeted agents
- Immunomodulatory and immunoconjugated
therapeutics
• Forecasts
PIPELINE ANGIOGENESIS INHIBITORS ANALYSIS &
FORECASTS
• Pipeline overview
• AstraZeneca's AZD2171
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• GlaxoSmithKline's Pazopanib (GW 786034)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Novartis/Schering AG's Vatalanib (PTK-787)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Sanofi Aventis/Regeneron's VEGF-Trap
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Forecasts
• Datamonitor drug assessment summary
PIPELINE SINGLE-TARGET SIGNAL TRANSDUCTION
INHIBITORS ANALYSIS & FORECASTS
• Pipeline overview
• Amgen's Vectibix (panitumumab; ABX-EGF)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Schering-Plough's Sarasar (Lonafarnib)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Abbott Laboratories' Xinlay (atrasentan)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Wyeth's Temsirolimus (CCI-779)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Janssen/Johnson & Johnson's Zarnestra
(tipifarnib)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• YM Bioscience's TheraCIM (Theraloc;
Nimotuzumab)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Forecasts
• Datamonitor drug assessment summary
PIPELINE MULTI-TARGETED INHIBITORS ANALYSIS &
FORECASTS
• Pipeline overview
• GlaxoSmithKline's Tykerb/Tycerb (Lapatinib)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• ChemGenex Pharmaceuticals' Ceflatonin (CGX635, Myelostat)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Ipsen's Somatuline (Lanreotide)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Novartis's Tasigna (Nilotinib, AMN-107)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• AstraZeneca's Zactima (Vandetanib; ZD6474)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Eli Lilly's Enzastaurin (LY317615)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Cephalon's Lestaurtinib (CEP-701)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Forecasts
• Datamonitor drug assessment summary
PIPELINE CELL CYCLE AND APOPTOSIS TARGETED
AGENTS ANALYSIS & FORECASTS
• Pipeline overview
• Genta's Genasense (Oblimersen)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Telik's Telcyta (TLK286)
- Drug Profile
- Clinical Trial Data
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies – More Drugs on the Market, More Targets in the Pipeline
DMHC2224
- Datamonitor Comments
• Celtic Pharma/Xenova's TransMID (XR-311)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Sanofi-Aventis's Alvocidib (Flavopiridol)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Novogen's Phenoxodiol
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Forecasts
• Datamonitor drug assessment summary
- Clinical, developmental and commercial
challenges to combining molecular targeted
therapies
• Case study two
- Comparing marketed and pipeline MTTs: The
evolving trends
APPENDIX
TABLES
Table 1:
Table 2:
Table 3:
PIPELINE EPIGENETIC MODULATORS ANALYSIS &
FORECASTS
• Pipeline overview
• Merck's Zolinza (Vorinostat, SAHA)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Gloucester Pharmaceuticals' Romidepsin (FK-228,
depsipeptide)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Forecasts
• Datamonitor drug assessment summary
PIPELINE IMMUNOMODULATORY AND
IMMUNOCONJUGATED THERAPEUTICS ANALYSIS &
FORECASTS
• Pipeline overview
• Wilex's Rencarex (WX-G250)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Genmab's Ofatumumab (HuMax-CD20)
- Drug Profile
- Clinical Trial Data
- Datamonitor Comments
• Forecasts
• Datamonitor drug assessment summary
Table 4:
Table 5:
Table 6:
Table 7:
Table 8:
Table 9:
Table 10:
Table 11:
Table 12:
Table 13:
Table 14:
Table 15:
Table 16:
Table 17:
Table 18:
Table 19:
COMMERCIAL IMPACT & LIFECYCLE MANAGEMENT:
CASE STUDIES
• Introduction
• Case study one
Table 20:
Table 21:
Table 22:
Molecular targeted therapies in preregistration,
2006
Molecular targeted therapies in Phase III
development, 2006
Pipeline molecular targeted therapies by
development phase and class of drug, 2006
Pipeline molecular targeted therapies by
indication, 2006
Specific target/targets with two candidates in
the pipeline, 2006
Specific target/targets with three or more
candidates in the pipeline, 2006
Number of products in the pipeline targeting
key molecular drivers of cancer, 2006
Companies with two candidates in the
molecular targeted therapies pipeline, 2006
Companies with three candidates in the
molecular targeted therapies pipeline, 2006
Companies with four or more candidates in the
molecular targeted therapies pipeline, 2006
Pfizer's marketed oncology portfolio, 2006
Pfizer's molecular targeted cancer therapies
portfolio, 2006
Novartis' marketed oncology portfolio, 2006
Novartis' molecular targeted cancer therapies
portfolio, 2006
GSK's marketed oncology portfolio, 2006
GSK's molecular targeted cancer therapies
portfolio, 2006
Late-phase pipeline targeted therapies sales
forecasts for the seven major markets ($m),
2006-2015
Datamonitor drug assessment summary for
late-phase pipeline molecular targeted cancer
therapies, 2006
Common mutations involved in tumor
development
Forecast incidence of cancer across the seven
major markets, 2005-2013
Examples of naturally occurring angiogenesis
stimulators
Recently approved multi-targeted inhibitors,
2006
Table 23: Current targeted therapy marketed products,
2006 (1 of 2)
Table 24: Current targeted therapy marketed products,
2006 (1 of 2)
Table 25: Targeted therapies sales in the seven major
markets, 2005
Table 26: Clinical pipeline for Nexavar, 2006
Table 27: Clinical pipeline for Sprycel, 2006
Table 28: Summary of Phase II Sprycel clinical trial
results
Table 29: Clinical pipeline for Sutent, 2006
Table 30: Approved indications for Rituxan in the US and
EU, 2006
Table 31: Late-phase pipeline angiogenesis inhibitors,
2006
Table 32: Phase II pipeline angiogenesis inhibitors, 2006
Table 33: Phase I pipeline angiogenesis inhibitors, 2006
Table 34: Ongoing clinical trials involving AZD2171, 2006
Table 35: Ongoing clinical trials involving pazopanib,
2006
Table 36: Ongoing clinical trials involving vatalanib, 2006
Table 37: Ongoing clinical trials involving VEGF-Trap,
2006
Table 38: Forecasting assumptions for late-phase
angiogenesis inhibitors, 2006
Table 39: Angiogenesis inhibitors sales forecasts ($m),
2006-2015
Table 40: Research/clinical and commercial
attractiveness of pipeline angiogenesis
inhibitors, 2006
Table 41: Late-phase pipeline single-target signal
transduction inhibitors, 2006
Table 42: Phase II pipeline single-target signal
transduction inhibitors, 2006
Table 43: Phase I pipeline single-target signal
transduction inhibitors, 2006
Table 44: Ongoing clinical trials involving Vectibix, 2006
Table 45: Ongoing clinical trials involving Sarasar, 2006
Table 46: Ongoing clinical trials involving Xinlay, 2006
Table 47: Historical development of Xinlay, 1994-2005
Table 48: Ongoing Phase II/III trials involving
temsirolimus, 2006
Table 49: Ongoing clinical trials involving Zarnestra, 2006
Table 50: Phase I/II trial involving Nexavar, Tarceva,
Temsirolimus and Zarnestra, 2006
Table 51: Forecasting assumptions for late-stage pipeline
single-target signal transduction inhibitors (1 of
2)
Table 52: Forecasting assumptions for late-stage pipeline
single-target signal transduction inhibitors (2 of
2)
Table 53: Single-target signal transduction inhibitors sales
forecasts ($m), 2006-2015
Table 54: Research/clinical and commercial
attractiveness of pipeline single-target signal
transduction inhibitors (1 of 2)
Table 55: Research/clinical and commercial
attractiveness of pipeline single-target signal
transduction inhibitors (2 of 2)
Table 56: Late-phase pipeline multi-targeted inhibitors,
2006
Table 57: Phase II pipeline multi-targeted inhibitors, 2006
Table 58: Phase I pipeline multi-targeted inhibitors, 2006
Table 59: Ongoing breast cancer clinical trials involving
Tykerb, 2006
Table 60: Ongoing non-breast cancer clinical trials
involving Tykerb, 2006
Table 61: Summary of key Tykerb breast cancer clinical
trials, 2006
Table 62: Ongoing clinical trials involving Ceflatonin,
2006
Table 63: Ongoing trials involving Somatuline, 2006
Table 64: Ongoing clinical trials involving Tasigna, 2006
Table 65: Zactima's multiple anticancer targets
Table 66: Ongoing clinical trials involving Zactima
Table 67: Ongoing clinical trials involving enzastaurin,
2006
Table 68: Ongoing clinical trials involving lestaurtinib
Table 69: Forecasting assumptions for late-stage pipeline
multi-targeted inhibitors (1 of 2)
Table 70: Forecasting assumptions for late-stage pipeline
multi-targeted inhibitors (2 of 2)
Table 71: Multi-targeted inhibitors sales forecasts ($m),
2006-2015
Table 72: Research/clinical and commercial
attractiveness of pipeline multi-targeted
inhibitors (1 of 2)
Table 73: Research/clinical and commercial
attractiveness of pipeline multi-targeted
inhibitors (2 of 2)
Table 74: Late-phase pipeline cell cycle and apoptosis
targeted agents, 2006
Table 75: Phase II pipeline cell cycle and apoptosis
targeted agents, 2006
Table 76: Phase I pipeline cell cycle and apoptosis
targeted agents, 2006
Table 77: Ongoing clinical trials involving Genasense,
2006
Table 78: Ongoing clinical trials involving Telcyta, 2006
Table 79: NSCLC clinical trial data summary for Telcyta,
2006
Table 80: Key Phase III trials of Telcyta for ovarian
cancer, 2006
Table 81: Ongoing clinical trials involving TransMID, 2006
Table 82: Ongoing clinical trials involving alvocidib, 2006
Table 83: Ongoing clinical trials involving phenoxodiol,
2006
“...I don't know what to tell the pharmaceutical companies…
There's got to be a strategy they can come up with so that their targeted drugs
are better justified to payers...”
US opinion leader,
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies – More Drugs on the Market, More Targets in the Pipeline
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies – More Drugs on the Market, More Targets in the Pipeline
DMHC2224
Table 84: Forecasting assumptions for late-stage pipeline
cell cycle and apoptosis targeted agents (1 of
2)
Table 85: Forecasting assumptions for late-stage pipeline
cell cycle and apoptosis targeted agents (2 of
2)
Table 86: Cell cycle and apoptosis targeted agents sales
forecasts ($m), 2006-2015
Table 87: Research/clinical and commercial
attractiveness of pipeline cell cycle and
apoptosis targeted agents
Table 88: Late-phase pipeline epigenetic modulators,
2006
Table 89: Phase II pipeline epigenetic modulators, 2006
Table 90: Phase I pipeline epigenetic modulators, 2006
Table 91: Ongoing clinical trials involving Zolinza, 2006
Table 92: Ongoing clinical trials involving romidepsin,
2006
Table 93: Zolinza forecasting assumptions
Table 94: Zolinza sales forecasts ($m), 2006-2015
Table 95: Research/clinical and commercial
attractiveness of Zolinza
Table 96: Late-phase pipeline immunomodulatory and
immunoconjugated therapeutics, 2006
Table 97: Phase II pipeline immunomodulatory and
immunoconjugated therapeutics, 2006
Table 98: Phase I pipeline immunomodulatory and
immunoconjugated therapeutics, 2006
Table 99: Ongoing clinical trial involving Rencarex, 2006
Table 100: Ongoing clinical trial involving ofatumumab,
2006
Table 101: Forecasting assumptions for late-phase
immunomodulatory and immunoconjugated
therapeutics
Table 102: Late-phase immunomodulatory and
immunoconjugated therapeutics sales forecasts
($m), 2006-2015
Table 103: Research/clinical and commercial
attractiveness of the late-phase
immunomodulatory and immunoconjugated
therapeutics
Table 104: Phase I/II trial involving Nexavar, Tarceva,
Temsirolimus and Zarnestra in GBM or
gliosarcoma patients, 2006
Table 105: Examples of combinatorial approaches of
MAbs with chemotherapy
Table 106: Comparative characteristics of small molecules
and MAbs
Table 107: Single agents versus multiple agents in
combination
Table 108: Marketed molecular targeted cancer therapies,
2006
Table 109: Rituxan: key facts
Table 110: Herceptin: key facts
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
111:
112:
113:
114:
115:
116:
117:
118:
119:
120:
121:
122:
123:
124:
125:
126:
Table 127:
Table 128:
Table 129:
Table 130:
Table 131:
Table 132:
Table 133:
Table 134:
Table 135:
Table 136:
Table 137:
Campath: key facts
Mylotarg: key facts
Bexxar: key facts
Avastin: key facts
Erbitux: key facts
Zevalin: key facts
Gleevec: key facts
Targretin: key facts
Iressa: key facts
Velcade: key facts
Tarceva: key facts
Sprycel: key facts
Nexavar: key facts
Sutent: key facts
Ontak: key facts
Forecasts for marketed targeted therapies for
the US ($m), 2005-2015
Forecasts for marketed targeted therapies for
Japan ($m), 2005-2015
Forecasts for marketed targeted therapies for
France ($m), 2005-2015
Forecasts for marketed targeted therapies for
Germany ($m), 2005-15
Forecasts for marketed targeted therapies for
Italy ($m), 2005-15
Forecasts for marketed targeted therapies for
Spain ($m), 2005-15
Forecasts for marketed targeted therapies in
the UK ($m), 2005-15
Forecasts for marketed targeted therapies for
the EU5 ($m), 2005-2015
Forecasts for marketed targeted therapies for
the seven major markets ($m), 2005-2015
Datamonitor drug assessment parameters
Abbreviations used in Pipeline/Commercial
Insight: Molecular Targeted Cancer Therapies
(1 of 2)
Abbreviations used in Pipeline/Commercial
Insight: Molecular Targeted Cancer Therapies
(2 of 2)
FIGURES
Figure 1: Pipeline molecular targeted therapies by
development phase and class of drug, 2006
Figure 2: Pipeline molecular targeted therapies by class
of drug, 2006
Figure 3: Pipeline molecular targeted therapies by
development phase, 2006
Figure 4: Angiogenesis inhibitors by developmental
phase, 2006
Figure 5: Single-target signal transduction inhibitors by
developmental phase, 2006
Figure 6: Multi-targeted inhibitors by developmental
phase, 2006
Figure 7: Cell cycle and apoptosis targeted agents by
developmental phase, 2006
Figure 8: Epigenetic inhibitors by developmental phase,
2006
Figure 9: Immunomodulatory and immunoconjugated
therapeutics by developmental phase, 2006
Figure 10: Pipeline molecular targeted therapies by solid
tumor indication, 2006
Figure 11: Pipeline molecular targeted therapies by
hematological malignancy, 2006
Figure 12: Number of products in the pipeline targeting
key molecular drivers of cancer, 2006
Figure 13: Companies with four or more candidates in the
molecular targeted therapies pipeline, 2006
Figure 14: Pipeline angiogenesis inhibitors sales forecasts
for the seven major markets ($m), 2006-2015
Figure 15: Pipeline single-target signal transduction
inhibitors sales forecasts for the seven major
markets ($m), 2006-2015
Figure 16: Pipeline multi-targeted inhibitors sales forecasts
for the seven major markets ($m), 2006-2015
Figure 17: Pipeline cell cycle and apoptosis targeted
agents sales forecasts for the seven major
markets ($m), 2006-2015
Figure 18: Pipeline epigenetic modulators sales forecasts
for the seven major markets ($m), 2006-2015
Figure 19: Pipeline immunomodulatory and
immunoconjugated therapeutics sales forecasts
for the seven major markets ($m), 2006-2015
Figure 20: Datamonitor drug assessment summary for
pipeline angiogenesis inhibitors, 2006
Figure 21: Datamonitor drug assessment summary for
pipeline single-target signal transduction
inhibitors, 2006
Figure 22: Datamonitor drug assessment summary for
pipeline multi-targeted inhibitors, 2006
Figure 23: Datamonitor drug assessment summary for
pipeline cell cycle and apoptosis targeted
agents, 2006
Figure 24: Datamonitor drug assessment summary for
epigenetic modulators, 2006
Figure 25: Datamonitor drug assessment summary for
immunomodulatory and immunoconjugated
therapeutics, 2006
Figure 26: Global oncology sales ($m), 2002-09
Figure 27: Oncology pipeline including supportive care,
2006
Figure 28: Forecast incidence of cancer across the seven
major markets, 2005-2013
Figure 29: Combined incidence for breast, lung, prostate
and colorectal cancer rises with age in seven
major markets, 2003
Figure 30: Incidence increases, while the rate of cure and
death reduces disease prevalence
Figure 31: Point prevalence for colorectal and lung cancer
differs markedly despite similar rates of
incidence
Figure 32: Unmet needs in cancer, 2006
Figure 33: The process of tumor angiogenesis
Figure 34: Approaches to inhibition of VEGF signaling
Figure 35: Angiogenesis inhibitors sales forecasts ($m),
2006-2015
Figure 36: Research/clinical and commercial
attractiveness of pipeline angiogenesis
inhibitors, 2006
Figure 37: Single-target signal transduction inhibitors sales
forecasts ($m), 2006-2015
Figure 38: Research/clinical and commercial
attractiveness of pipeline single-target signal
transduction inhibitors, 2006
Figure 39: Design of Phase III Tykerb plus capecitabine
versus capecitabine alone trial
Figure 40: Multi-targeted inhibitors sales forecasts ($m),
2006-2015
Figure 41: Research/clinical and commercial
attractiveness of pipeline multi-targeted
inhibitors
Figure 42: Telcyta's mechanism of action
Figure 43: TransMID's mode of action
Figure 44: Cell cycle and apoptosis targeted agents sales
forecasts ($m), 2006-2015
Figure 45: Research/clinical and commercial
attractiveness of pipeline cell cycle and
apoptosis targeted agents
Figure 46: Zolinza sales forecasts ($m), 2006-2015
Figure 47: Research/clinical and commercial
attractiveness of Zolinza
Figure 48: Rencarex induced ADCC
Figure 49: Rencarex Phase II results: median survival
Figure 50: Late-phase immunomodulatory and
immunoconjugated therapeutics sales forecasts
($m), 2006-2015
Figure 51: Research/clinical and commercial
attractiveness of the late-phase
immunomodulatory and immunoconjugated
therapeutics, 2006
Figure 52: Number of marketed MAbs and small
molecules, 2006
Figure 53: Number of late-phase MAbs and small
molecules, 2006
Figure 54: Number of marketed molecular targeted
therapies for solid tumors and hematological
malignancies, 2006
Figure 55: Number of late-phase molecular targeted
therapies for solid tumors and hematological
malignancies, 2006
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies – More Drugs on the Market, More Targets in the Pipeline
DMHC2224
Figure 56: Number of molecular targeted therapies
approved in the 'big four' tumor types, 2006
Figure 57: Number of late-phase molecular targeted
therapies in the 'big four' tumor types, 2006
Figure 58: Marketed molecular targeted therapies by
indication, 2006
Figure 59: Phase I, II and III molecular targeted therapies
by indication, 2006
Figure 60: Approval paths of the marketed molecular
targeted therapies
Figure 61: Advantages and disadvantages of developing
an MTT in one of the 'Big Four' tumor types
Figure 62: Advantages and disadvantages of developing
an MTT in a niche tumor type
Figure 63: Example of Datamonitor drug assessment
scorecard
Figure 64: Example of Datamonitor drug assessment
graph
Datamonitor: Your total information solution
Datamonitor is a premium business information company helping 5,000 of the world's leading
companies across the Automotive, Consumer Markets, Energy, Financial Services, Healthcare
and Technology sectors.
Our products and services are specifically designed to support our clients’ key business
processes – from corporate strategy to competitive intelligence. We provide an independent and
trustworthy source of data, analysis and forecasts to improve these processes and ultimately, to
help grow your business.
Corporate Strategy
& Business Planning
Quality
Data
Product Development
& Commercialization
Make more effective strategic
and business decisions
Accelerate delivery
of commercial success
HELPING
TO GROW
YOUR
BUSINESS
Expert
Analysis
Assess and influence your
commercial and market
environment
Targeting &
Influencing the Market
Market &
Competitive Intelligence
Future
Forecasts
Maintain or obtain critical
competitive advantage
Nothing speaks louder than our clients
3M
Abbott
Accenture
Alcon Labs
Allergan
Almirall-Prodesfarma
Altana Pharma AG
Amersham
Amgen
Amrad
Angelini Acraf
Astellas
AstraZeneca
AT Kearney
Baxter
Bayer Healthcare AG
Beaufour Ipsen
Biochemie
Biogen Idec
Boehringer Ingelheim
Boots
Bristol-Myers Squibb
Cantab
Caremark International
Chiesi
Chiron
Chugai
CMC Co
Daiichi
Deutsche Morgan
Grenfell
Elan
Eli Lilly
Esteve
Flamel
Fournier
Gehe
Genzyme
Gilead
Gist Brocades
GlaxoSmithKline
IBM
Immuno AG
Johnson & Johnson
Jouveinal
LEK
Lipha
Lundbeck
Merck KGaA
Merck & Co
Millennium
Pharmaceuticals
Nabi Biopharmaceuticals
Novartis
Novo Nordisk
Pfizer
Pharmachemie
Pierre Fabre
Pliva
Procter & Gamble
Ranbaxy
Recordati
Sankyo
sanofi-aventis
Schering AG
Schering-Plough
Schwarz Pharma AG
Serono
Shire Pharmaceuticals
Solvay Pharmaceuticals
Takeda
TAP Pharmaceutical
Teva
UCB
Uriach
Vernalis
Viatris
Wyeth
“...89% of our clients use Datamonitor research
to develop competitive intelligence...”
Source: Datamonitor Customer Research
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies – More Drugs on the Market, More Targets in the Pipeline
DMHC2224
Interested in this topic?
Datamonitor’s Oncology portfolio features detailed analysis of development
pipelines, current and future market dynamics, patient potential, treatment
patterns, and strategic issues, to highlight latest market trends and new
commercial opportunities.
- Hormonal Therapies
- Innovative Therapies
- Cytotoxic Therapies
- Key tumor types: breast, colorectal, lung, ovarian, prostate, niche
Also available in this portfolio
Stakeholder Insight: Non Small Cell Lung Cancer
Treatment and physician persectives on NSCLC
Published: Sep-06
Product code: DMHC2223
Commercial Insight: Top 20 Cancer Therapeutics – New treatment paradigms
transforming market outlook
Analysis of the current and future potential of the cancer market in terms of the Top 20 leading
therapeutics. Includes in-depth profiles and sales forecasts to 2015 across the seven major
markets in light of key events to influence product revenues.
Published: Jul-06
Product code: DMHC2182
Pipeline Insight: Cancer Overview – Emerging therapeutic and commercial opportunities
Analysis of pipeline agents for 11 tumor types (breast, brain, colorectal, gastric, head and neck,
hepatocellular, non-small cell lung, ovarian, pancreatic, prostate and renal cell), including sales
forecasts to 2016 and Datamonitor drug assessment.
Published: Jul-06
Product code: DMHC2183
MCS Stakeholder Insight: Colorectal Cancer – Integration of targeted therapies changing
the standard of care
Increasing choices for prescribers, understanding how best to integrate innovative therapies in
to current practice and the significant cost implications for payers are impacting on existing
treatment paradigms across the major markets.
Published: Jun-06
Product code: DMHC2174